Wordt geladen...
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
HDAC inhibitors (HDACI) are now emerging as one of the most promising new classes of drugs for the treatment of select forms of non-Hodgkin’s lymphoma (NHL). They are particularly active in T-cell lymphomas, possibly hodgkin’s lymphoma and indolent B cell lymphomas. Presently, two of these agents, v...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer US
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3003796/ https://ncbi.nlm.nih.gov/pubmed/21132350 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9591-3 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|